SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NKTR reported Third Quarter 2026 results. The stock moved +0.1% on the print.
NKTRearnings

Earnings reactions, page 3

Nektar Therapeutics (NKTR) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue in the third quarter of 2026 was $9.4 million as compared to $11.8 million in the third quarter of 2025.
  • Net loss for the third quarter of 2026 was $55.7 million, or $1.63 basic and diluted net loss per share, as compared to a net loss of $35.5 million, or $1.87 basic and diluted loss per share, in the third quarter of 2025.
  • Research and development (R&D) expense in the third quarter of 2026 was $44.1 million as compared to $27.3 million for the third quarter of 2025.
  • General and administrative (G&A) expense was $24.6 million in the third quarter of 2026 as compared to $16.1 million in the third quarter of 2025.
  • Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025.

Price and volatility reaction

The stock moved +0.1% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release37.252026-11-12
Close after release37.272026-11-13
Realised move+0.1%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →